Medical Genetics | Methods for Diagnostic & Therapeutic Studies | Liver Failure & Liver Disease | Viral Hepatitis
IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B (CHB) patients treated with pegylated interferon-alpha
JA Holmes*, T Nguyen, D Ratnam, NM Heerasing, JV Tehan, S Bonanzinga, AT Dev, SJ Bell, S Pianko, K Visvanathan, F Rusli, S Locarnini, W Sievert, PV Desmond, DS Bowden, AJ Thompson
*Corresponding author: JA Holmes
Department of Gastroenterology, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia
F1000Posters 2012, 3: 615 (poster) [English]
Poster [1.13 MB]
Presented at
47th Annual International Liver Congress 2012,
18 - 22 Apr 2012, 514
In this study we investigated whether the IL28B genotype is associated with treatment outcomes in a predominantly Asian chronic hepatitis B (CHB) cohort treated with pegylated interferon (pIFN) monotherapy. We were also interested in identifying predictors of pIFN response in this specific cohort.
There was no association between the IL28B genotype and pIFN treatment response in this cohort of predominantly Asian CHB patients. The high frequency of the CC IL28B genotype in Asian CHB patients suggests that IL28B genotyping prior to pIFN therapy for CHB will not be useful.
No relevant competing interests disclosed.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
